NCT05786924 2025-11-20Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive MalignanciesServierPhase 1/2 Recruiting554 enrolled
NCT04521686 2025-06-27Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 MutationsEli Lilly and CompanyPhase 1 Active not recruiting200 enrolled